Streetbeat News

Earnings

BIRD

Allbirds shares are trading lower following the company's announcement of weak guidance for future performance.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:05 am

ZIM

ZIM Integrated Shipping projects its FY24 adjusted EBITDA to be between $850M and $1.45B, with an adjusted EBIT ranging from a loss of $300M to a gain of $300M.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:04 am

GHLD

Guild Holdings shares are trading lower following the announcement of worse-than-expected Q4 revenues.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:04 am

RXT

Rackspace Technology's shares dropped following the announcement of Q1 guidance below expectations and refinancing transactions.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:04 am

WOOF

Petco Health and Wellness (WOOF) reported Q4 adjusted earnings of $0.02 per share, meeting analyst estimates, but marking a 91.3% decrease from last year's $0.23. Quarterly sales reached $1.67 billion, exceeding the $1.62 billion estimate and showing a 6.08% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:03 am

WOW

WideOpenWest (NYSE:WOW) reported Q4 losses of $(0.54) per share, missing the $(0.01) estimate by 5300%, and a 260% decrease from last year. Sales were $168.80M, missing the $170.57M estimate by 1.04%, and a 6.48% decrease from last year.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:03 am

CLOV

Clover Health Investments' shares surged following the announcement of better-than-expected Q4 revenue results and the issuance of optimistic FY24 insurance revenue guidance.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:03 am

SWIM

Latham Group's shares are trading lower following the announcement of their Q4 financial results.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:03 am

IONS

Ionis Pharmaceuticals, Inc. announced positive results from a Phase 2 study of ION224, a treatment for metabolic dysfunction-associated steatohepatitis (MASH), meeting primary and important secondary endpoints.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:03 am

MXCT

MaxCyte shares surged following the announcement of their Q4 financial results, which exceeded expectations. Additionally, the company provided positive guidance for FY24.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:03 am